Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells
- 1 October 1988
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 73 (2-3) , 173-180
- https://doi.org/10.1016/0021-9150(88)90039-1
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Non-competitive enzyme-linked immunosorbent assay for human apolipoprotein SAA or SJournal of Immunological Methods, 1988
- Metabolism of apolipoprotein C-III in normolipemic human subjectsAtherosclerosis, 1988
- Plasma lipoprotein changes in humans induced by β-interferonAtherosclerosis, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Polypetide mediator networkNature, 1987
- Comparison of different sandwich enzyme immunoassays for the quantitation of human apolipoproteins A-I and A-IIJournal of Immunological Methods, 1987
- Multiple Biological Properties of Recombinant Human Interleukin 1 (beta)Immunobiology, 1986
- Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophagesBiochemical and Biophysical Research Communications, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1982